ReviewCurrent rheumatology reports2013
The future of osteoarthritis therapeutics: emerging biological therapy.
Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 79 citations in OpenAlex.
- Measurement of bone marrow lesions by MR imaging in knee osteoarthritis using quantitative segmentation methods--a reliability and sensitivity to change analysis.BMC musculoskeletal disorders · 2014Trial
- Inhibition of Cathepsin C attenuates osteoarthritis by modulating macrophage activated status and reducing tissue inflammatory responses.Bone & joint research · 2026Article
- The renin-angiotensin system (RAS) and arthritic diseases: therapeutic potential for RAS inhibitors.Inflammopharmacology · 2025Review
- Advancing osteoarthritis management: integrating new insights and addressing persistent roadblocks.Inflammopharmacology · 2025Review
- Low-Grade Inflammatory Mediators and Metalloproteinases Yield Synchronous and Delayed Responses to Mechanical Joint Loading.Cartilage · 2024Article
- Harnessing exosomes for advanced osteoarthritis therapy.Nanoscale · 2024Review
- Bioinformatics analysis of synovial fluid-derived mesenchymal stem cells in the temporomandibular joint stimulated with IL-1β.Cytotechnology · 2023Article
- Construction of a Diagnostic mBiomolecules · 2023Article
- The Role of Regulated Programmed Cell Death in Osteoarthritis: From Pathogenesis to Therapy.International journal of molecular sciences · 2023Review
- Osteoarthritis: Can We Do Better?Cureus · 2022Review
- The role of extracellular vesicles in osteoarthritis treatment via microenvironment regulation.Biomaterials research · 2022Review
- Polymeric Hydrogels for Controlled Drug Delivery to Treat Arthritis.Pharmaceutics · 2022Review
- Identification and development of a novel 5-gene diagnostic model based on immune infiltration analysis of osteoarthritis.Journal of translational medicine · 2021Article
- Hyperosmolar Ionic Solutions Modulate Inflammatory Phenotype and sGAG Loss in a Cartilage Explant Model.Cartilage · 2021Article
- Sulforaphane protects against oxidative stress‑induced apoptosis via activating SIRT1 in mouse osteoarthritis.Molecular medicine reports · 2021Article
- CircSLC7A2 protects against osteoarthritis through inhibition of the miR-4498/TIMP3 axis.Cell proliferation · 2021Article
- Editorial: One Step at a Time: Advances in Osteoarthritis.Frontiers in veterinary science · 2021Article
- Circular RNA CSNK1G1 promotes the progression of osteoarthritis by targeting the miR‑4428/FUT2 axis.International journal of molecular medicine · 2021Article
- Review
- Anti-Inflammatory and Chondroprotective Effects of Vanillic Acid and Epimedin C in Human Osteoarthritic Chondrocytes.Biomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Biological therapy is a thriving area of research and development, and is well established for chronic forms of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, there is no clinically validated biological therapy for osteoarthritis (OA). Chronic forms of OA are increasingly viewed as an inflammatory disease. OA was largely regarded as a "wear and tear disease". However, the disease is now believed to involve "low grade" inflammation and the growth of blood vessels and nerves from the subchondral bone into articular cartilage. This realization has focused research effort on the development and evaluation of biological therapy that targets proinflammatory mediators, angiogenic factors and cytokines in articular cartilage, subchondral bone and synovium in chronic forms of OA. This review article provides an overview of emerging biological therapy for OA, and discusses recent molecular targets implicated in angiogenesis and neurogenesis and progress with antibody-based therapy, calcitonin, and kartogenin, the small molecule stimulator of chondrogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.